Gene Therapy for Hemophilia B: Aav-Mediated Transfer of The Gene for Coagulation Factor IX to Human Muscle

  • Peter J. Larson
  • Katherine A. High
Part of the Advances in Experimental Medicine and Biology book series (AEMB, volume 489)

Abstract

Hemophilia B is an X-linked bleeding disorder caused by a deficiency of coagulation factor IX. In its severe form, the disease results in spontaneous bleeding as well as bleeding following surgery or trauma, and is clinically indistinguishable from hemophilia A (factor VIII deficiency). The major morbidity of the disease is the chronic arthropathy of hemophilia that develops following spontaneous hemorrhage into the joint spaces. Blood in the joint space serves as an irritant causing proliferation of the vascular synovial membranes. Hypertrophied synovium is more susceptible to injury resulting in a vicious cycle of rebleeding that furthers the destruction of the joint. The major bleeding-related mortality of hemophilia is intracranial hemorrhage that occurs in between 3 and 14% of patients (1, 2, 3). The mortality rate from intracranial hemorrhage ranges from 20–50%, and survivors are often left with severe neurological sequelae such as seizures, paresis or mental retardation (1). Current treatment of hemophilia is based on the episodic intravenous infusion of highly purified plasma-derived or recombinant clotting factor concentrates in response to bleeding episodes (on-demand therapy).

Keywords

Toxicity Hepatitis Recombinate Bilirubin Creatine 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Eyster ME, Gill FM, Blatt PM, Hilgartner MW, Ballard JO and Kinney TR Central nervous system bleeding in hemophiliacs. Blood 51:1179–1188, 1978.PubMedGoogle Scholar
  2. 2.
    Andes WA, Wulff K and Smith WB. Head trauma in hemophilia: a prospective study. Arch Int Med 144:1981–1983, 1984.CrossRefGoogle Scholar
  3. 3.
    Bray GL and Lubahn NL. Hemophilia presenting with intracranial hemorrhage. An approach to the infant with intracranial bleeding and coagulopathy. Amer J Dis Child 141:1215–1217, 1987.PubMedGoogle Scholar
  4. 4.
    Lofqvist T, Nilsson IM, Berntorp E and Pettersson H. Haemophilia prophylaxis in young patients--a long-term follow-up. Journal of Internal Medicine 241:395–400, 1997.PubMedCrossRefGoogle Scholar
  5. 5.
    Ljung RCR. Annotation. Can haemophilic arthropathy be prevented? Brit J Haematol 101:215–219, 1998.CrossRefGoogle Scholar
  6. 6.
    Lyon DJ, Chapman CS, Martin C, Brown KE, Clewley JP, Flower AJE and Mitchell VE. Symptomatic parvovirus B19 infection and heat-treated factor IX concentrate. (letter). Lancet 1:1985, 1989.Google Scholar
  7. 7.
    Laurian Y, Dussaix E, Parquet A, Chalvon-Demersay A, d’Oiron R and Tchemia G. Transmission of human parvovirus B19 by plasma derived factor VIII concentrates. Nouv Rev Fr Haematol 36:449–453, 1994.Google Scholar
  8. 8.
    Santagostino E, Mannucci PM, Gringeri A and al. e. Transmission of parvovirus B19 by coagulation factor concentrates exposed to 100¡ãC heat after lyophilization. Transfusion 37:517–522, 1997.PubMedCrossRefGoogle Scholar
  9. 9.
    Linnen I, Wages Jr J, Zhang-Keck Z-Y, Fry K, Krawczynski K, Alter H, Koonin E, Gallagher M, Alter M, Hadziyannis S, Karayiannis P, Fung K, Nakatsuji Y, Shih JW-K, Young L, Piatak Jr. M, Hoover C, Fernandez J, Chen S, Zou J-C, Morris T, Hyams K, Ismay S, Lifson J, Hess G, Foung S, Thomas H, Bradley D, Margolis H and Kim J. Molecular cloning and disease association of hepatitis G virus: A transfusion-transmissible agent. Science 271:505–508, 1996.PubMedCrossRefGoogle Scholar
  10. 10.
    Naoumov NV, Petrova EP, Thomas MG and Williams R. Presence of a newly described human DNA virus (TTV) in patients with liver disease. Lancet 352:195–197, 1998.PubMedCrossRefGoogle Scholar
  11. 11.
    Snyder E and Lipton K. Association Bulletin 94–4--Hepatitis G virus: status report and assessment of clinical relevance. AABB News Briefs August 1998:20–21, 1998.Google Scholar
  12. 12.
    Evans JP, Brinkhous KM, Brayer GD, Reisner HW and High KA. Canine hemophilia B resulting from a point mutation with unusual consequences. Proc Natl Acad Sci USA 86:10095–10099, 1989.PubMedCrossRefGoogle Scholar
  13. 13.
    Cameron C, Notley C, Hoyle S, McGlynn L, Hough C, Kamisue S, Giles A and Lillicrap D. The canine factor VIII cDNA and 5 flanking sequence. Thromb Haemost 79:317–322, 1998.PubMedGoogle Scholar
  14. 14.
    Bi L, Lawler AM, Antonarakis SE, High KA, Gearhart JD and Kazazian HI-I. Targeted disruption of the mouse factor VIII gene: A model for hemophilia A. Nature Genet. 10:119–121, 1995.PubMedCrossRefGoogle Scholar
  15. 15.
    Lin H-F, Maeda N, Smithies O. Straight DL and Stafford DW. A coagulation factor IX-deficient mouse model for human hemophilia B. Blood 90:3962–3966, 1997.PubMedGoogle Scholar
  16. 16.
    Snyder R, Xiao X and Samuiski R. Production of recombinant adeno-associated viral vectors in N. e. a. Dracopoli. Current Protocols in Human Genetics. New York, John Wiley & Sons. 1–24. 1996.Google Scholar
  17. 17.
    Kaplitt MG, Leone R, Samulski RJ, Xiao X, Pfaff DW, O’Malley KL and During MJ. Long-term expression and phenotypic correction using adeno-associated virus vectors in the mammalian brain. Nature Genet 8:148–154, 1994.PubMedCrossRefGoogle Scholar
  18. 18.
    Kessler PD, Podsakoff GM, Chen X, McQuiston SA, Colosi PC, Matelis LA, Kurtzman GJ and Bryne BJ. Gene delivery to skeletal muscle results in sustained expression and systemic delivery of a therapeutic protein. Proc Natl Acad Sci USA 93:14082–14087, 1996.PubMedCrossRefGoogle Scholar
  19. 19.
    Herzog R, Yang E, Couto L, Hagstrom J, Elwell D, Fields P, Burton M, Bellinger D, Read M, Brinkhous K, Podsakoff G, Nichols T, Kurtzman G and High K. Long-term correction of canine hemophilia B by gene transfer of blood coagulation factor IX mediated by adeno-associated viral vector. Nature Medicine 5:56–63, 1999.PubMedCrossRefGoogle Scholar
  20. 20.
    Tawa N and Goldberg A. Myology. New York, McGraw-Hill, Inc. 1994.Google Scholar
  21. 21.
    Lusher JM, Arkin S, Abildgaard CF and Schwartz RS. Recombinant factor VIII for the treatment of previously untreated patients with hemophilia A. New Engl J Med 328:453–459, 1993.PubMedCrossRefGoogle Scholar
  22. 22.
    Bray GL, Gomperts ED, Courter S, Gruppo R, Gordon EM, Manco-Johnson M, Shapiro A, Scheibel E, White G and Lee M. A multicenter study of recombinant factor VIII (recombinate): Safety, efficacy, and inhibitor risk in previously untreated patients with hemophilia A. Blood 83:2428–2435, 1994.PubMedGoogle Scholar
  23. 23.
    Schwarzinger I, Pabinger I, Kominger C, Haschke F, Kundi M, Neissner H and Lechner K. Incidence of inhibitors in patients with severe and moderate hemophilia A treated with factor VIII concentrates. Am J Hematol 24:241, 1987.PubMedCrossRefGoogle Scholar
  24. 24.
    Rasi V and Ikkala E. Haemophiliacs with factor VIII inhibitors in Finland: Prevalence, incidence and outcome. Brit J Haematol 76:369, 1990.CrossRefGoogle Scholar
  25. 25.
    Ehrenforth S, Kreuz W, Scharrer I, Linde R, Fund M, Gungor T, Krackhardt B and Komhuber B. Incidence of development of factor VIII and factor IX inhibitors in haemophiliacs. Lancet 339:594, 1992.PubMedCrossRefGoogle Scholar
  26. 26.
    Hoyer LW. The incidence of factor VIII inhibitors in patients with severe hemophilia A. Adv Exper Med & Biol 386:35–46, 1995.CrossRefGoogle Scholar
  27. 27.
    Kazazian HH. An estimated frequency of endogenous insertional mutations in humans. Nat Genet 22:130, 1999.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2001

Authors and Affiliations

  • Peter J. Larson
    • 1
  • Katherine A. High
    • 1
  1. 1.Department of Pediatrics, University of Pennsylvania School of MedicineThe Children’s Hospital of Philadelphia

Personalised recommendations